Pacific Edge Limited Stock price

Equities

PEB

NZPEBE0002S1

Biotechnology & Medical Research

End-of-day quote New Zealand S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.085 NZD -1.16% Intraday chart for Pacific Edge Limited 0.00% -27.35%
Sales 2024 * - Sales 2025 * - Capitalization 69M 116M
Net income 2024 * -28M -46.91M Net income 2025 * -20M -33.51M EV / Sales 2024 * -
Net cash position 2024 * 48.05M 80.5M Net cash position 2025 * 24.7M 41.39M EV / Sales 2025 * -
P/E ratio 2024 *
-2.45 x
P/E ratio 2025 *
-3.32 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.97%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.16%
Current month-1.16%
1 month-3.41%
3 months-21.30%
6 months-33.07%
Current year-27.35%
More quotes
1 week
0.08
Extreme 0.082
0.09
1 month
0.08
Extreme 0.082
0.09
Current year
0.08
Extreme 0.082
0.13
1 year
0.05
Extreme 0.05
0.50
3 years
0.05
Extreme 0.05
1.59
5 years
0.05
Extreme 0.05
1.59
10 years
0.04
Extreme 0.0385
1.59
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-01-16
Director of Finance/CFO - 19-12-15
Chief Tech/Sci/R&D Officer - 03-12-31
Members of the board TitleAgeSince
Chairman - 16-06-30
Director/Board Member 74 13-07-03
Director/Board Member - 22-03-20
More insiders
Date Price Change Volume
24-03-28 0.085 -1.16% 283,485
24-03-27 0.086 0.00% 575,033
24-03-26 0.086 +2.38% 1,131,710
24-03-25 0.084 -1.18% 1,427,620
24-03-22 0.085 0.00% 391,515

End-of-day quote New Zealand S.E., March 27, 2024

More quotes
Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas, and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.085 NZD
Average target price
0.145 NZD
Spread / Average Target
+70.59%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Pacific Edge Limited - New Zealand S.E.